The search for an integrated clinical research management system came to an end in February when Dana-Farber/Harvard Cancer Center (DF/HCC) selected the OnCore® system.
“At some level, we’ve been looking for a product over a decade,” said Jeffrey W. Clark, MD, Medical Director of Clinical Trials Operations at DF/HCC. Unfortunately, a system that was sophisticated enough to handle the complexity of Dana-Farber/Harvard Cancer Center’s seven-institution consortium did not exist until recently.
“In many ways, we had gone as far as we could in improving the operation. What was really missing were the integrated systems that would give us the automation, information, and management decision making tools to take our clinical trials program to the next level,” said Beverly Ginsburg-Cooper, MBA, Associate Director for Administration at DF/HCC and Senior VP for Research at Dana-Farber Cancer Institute.
Currently, DF/HCC uses informatics to support its clinical research operation. However, these systems are not fully integrated and there are opportunities to eliminate the duplication of effort and enhance the flow of data.
DF/HCC is comprised of seven separate independent institutions that function as a cohesive consortium. The center has a unified clinical trials structure with a single IRB, a single Protocol Review and Monitoring System, a single Data Safety and Monitoring Process, a single set of operating policies and procedures, and a centralized clinical trials infrastructure to support these functions. Additionally, the center has coordinated budgeting and contracting processes. But, each institution coordinates its own data management activities independently.
Immediately, the goal is to start using OnCore for all of the centralized administrative functions at DF/HCC. Additionally, there are several existing systems in place at the center that are under consideration for direct integration with OnCore. DF/HCC will also be identifying any critical functionality they would like to see added to OnCore.
Working Together to Improve Cancer Research and Care
The implementation of OnCore was kicked-off earlier this month at DF/HCC, and the center has already started participating in user community events and activities through Onsemble, a community comprised of OnCore users and others concerned with improving clinical research operations.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.